Clinical potential of long non-coding RNA LINC01133 as a promising biomarker and therapeutic target in cancers.
Uttam SharmaTushar Singh BarwalMasang MurmuVarnali AcharyaNeha PantDamayanti Deynull VivekAshima GautamSonali BazalaIpsa SinghFarah AzzouzAnupam BishayeeAklank JainPublished in: Biomarkers in medicine (2022)
Recently, long intergenic non-protein coding RNA 01133 ( LINC01133 ) was identified as a novel transcript in cancers. It modulates various hallmarks of cancers and acts as oncogenic in some cancers while tumor-suppressive in others. Furthermore, the expression of LINC01133 correlates with tumor size, advanced tumor node metastasis stage and lymphatic node metastasis, Ki-67 levels and overall survival of patients. Herein, the authors provide an in-depth analysis describing how LINC01133 modulates the multiple cancer-associated signaling pathways and the pathogenesis of various malignancies and treatment regimens. Based on the role played by LINC01133 , the authors propose LINC01133 as both a potential biomarker and a therapeutic target in cancer.
Keyphrases
- long non coding rna
- poor prognosis
- lymph node
- long noncoding rna
- end stage renal disease
- cell proliferation
- signaling pathway
- chronic kidney disease
- ejection fraction
- squamous cell carcinoma
- oxidative stress
- transcription factor
- childhood cancer
- risk assessment
- peritoneal dialysis
- optical coherence tomography
- rna seq
- young adults
- neoadjuvant chemotherapy
- patient reported outcomes
- replacement therapy
- induced apoptosis